Empowering clinical laboratories
by supplying them with a fully integrated system to perform a large menu of automated, cost-effective and easy to use tests with a high degree of accuracy and sensitivity.
Since the Company’s inception in 1999, scientists and engineers at AutoGenomics have endeavored to create automated technologies that simplify the complex test processes inherent in genetic analysis within a format that is user friendly and increases productivity in the clinical laboratory.
The INFINITI® system is designed specifically for processing AutoGenomics’ unique proprietary BioFilmChip® microarrays that can be multiplexed and configured with hundreds of biomarkers to assess disease signatures from a single sample specimen.
The INFINITI® system provides clinical laboratories with significant improvements in laboratory productivity, workflow and cost per reportable result.
The power to predict can strengthen the ability to heal and prevent disease. That’s why AutoGenomics, a Prescient Medicine company, is dedicated to uncovering critical insights that enable more informed, more effective care. We see this as the next frontier in healthcare, and we’re passionate about bringing it to life today. The need is critical, the technology is ready, and the time is now.
Through our expertise in pharmacology, chemistry, pathology, pharmacogenomics, and toxicology, we’ve created powerful tests, instruments and analytics that deliver the right information necessary to make the correct choice at the appropriate time. With actionable results in hand, physicians can better prescribe compatible therapies and also predict how a patient might react to potential treatment options.
Dr. Keri Donaldson
Chief Executive Officer and Head of Science / R&D
Dr. Donaldson’s work as Medical Director and CEO of Prescient Medicine is fueled by an extensive background in the fields of pathology, genomics, and diagnostics. An active ad hoc reviewer and consultant, Dr. Donaldson has earned a reputation as an innovative member of the medical community and garnered key positions within respected institutions and national committees. Throughout his time with Penn State College of Medicine, he’s served as Assistant Professor of Pathology (also at Hershey Medical Center), Assistant Professor of Public Health Sciences (a joint appointment also at Hershey Medical Center), Assistant Professor of Medicine, and Assistant Professor of Biochemistry. He was certified as a diplomate of both the American Board of Pathology and the National Board of Medical Examiners, and is a frequent guest speaker at regional and national symposia. Dr. Donaldson holds a BS from Pennsylvania State University, an MD from Temple University School of Medicine, and a master of science in clinical epidemiology (MSCE) from the University of Pennsylvania School of Medicine.
Head of Operations and Technology
With more than 20 years of experience in systems development, implementation and integration, Brian delivers a wide range of expertise in his work with Prescient Medicine. He serves as head of the Technology Team in the development of laboratory information systems, analytics, and smart app platforms. His responsibilities include the vision, strategy, and implementation of all aspects of information technology, telecommunications, and client operations. Before joining Prescient Medicine, Brian held multiple leadership positions at CVS Health, including a Senior Director role in which he managed day-to-day client operations and technology development for an $18 billion client portfolio with a $300 million technology budget. His time spent supporting automating and initiatives within new health plan features, regulatory and compliance controls, disease management applications, prescription fulfillment, and adjudication solutions earned him multiple “CVS Breakthrough” awards in recognition of technology achievements and innovation. Brian has a Bachelor of Arts in economics/accounting from the University of Illinois.
Head of Sales and Marketing
Kevin is a leader, executive and general manager with 20+ years of experience building and leading commercial teams and operations. Kevin comes to Prescient from Morningstar, Inc, a global investment research company, where he spent 15 years and most recently led the Global Markets Group. In this role, he was responsible for operations in 26 countries with 400+ employees and annual revenue of $225 million. Over his career, Kevin has held leadership roles responsible in client service, software operations, product management, sales management and P&L management. Kevin has demonstrated his ability to enter and build businesses in new markets through developing and executing go-to-market strategies across a variety of business lines. He excels at building high-performing teams in marketing, sales, product development and service to drive revenue growth, scalability and profitability. Kevin received his Bachelor of Arts from Dartmouth College in 1994 and an MBA in general management, marketing and technology from the Kellogg School of Management in 2002.
Vice President, Regulatory Affairs
Mrs. Lopez joined AutoGenomics in 2006 and has over 30 years of regulatory/clinical affairs/quality assurance experience in medical devices and pharmaceuticals companies. Her experience includes US and international regulations related to clinical trials/premarket submissions (PMA, IDE, 510k, MDD/IVDD) and quality systems (FDA QSR, ISO), as well as activites related to strategic planning, contract manufacturing, and mergers/acquisitions. Mrs. Lopez served as Vice President, Regulatory & Quality Assurance for Novatrix Biomedical, Director of Clinical Affairs at Micro Therapeutics, and Director of Regulatory Affairs at Cryogen. Mrs. Lopez holds a B.S. in Chemical Engineering from the Philipines, and a M.S. in Operations Research from Stanford University.
Sherman Chang, Ph.D.
Vice President, R&D Chemistry
Dr. Chang joined AutoGenomics as Senior Director of R&D Chemistry in 2013 and was appointed as Vice President of R&D Chemistry in January 2016. Prior to that, Dr. Chang was Senior Director of R&D at DermTech International (a biotech startup company in La Jolla, CA) where he developed a disruptive non-invasive melanoma cancer diagnostic test currently used in the market. Dr. Chang brings over 20 years of experience in R&D and In Vitro Diagnostics (IVD). Dr. Chang was the recipient of the 2017 AACC industry division poster award/certificate for genetic risk assessment of Opioid Addiction. Dr. Chang holds a B.S.in Pharmacy & M.S. in Biochemistry from National Taiwan University and a Ph.D. in Molecular Biology from University of Pittsburgh. Dr. Chang completed his post-doctoral research training at the Salk Institute and UCSD.
Dr. Laurence M. Demers
A clinical biochemist at Prescient Medicine, Dr. Laurence M. Demers (DABCC, FACB) is an accomplished researcher, author of medical texts, and clinical trial investigator—within both the pharmaceutical and in vitro diagnostic industries. His research is concentrated in molecular diagnostics, laboratory automation, thyroid disease, metabolic bone disease and breast cancer, leading to authorship on over 720 publications. Dr. Demers’s past and present board memberships include standouts such as President of the American Association for Clinical Chemistry, President of the National Academy of Clinical Biochemistry, the founding Director of Clinical Chemistry at the M.S. Hershey Medical Center, founding Director of the Core Endocrine Laboratory in the Pennsylvania State University Hospital, Chairman of the Board of Trustees of Merrimack College, and Director of the Pennsylvania State Clinical Research Center Core Laboratory. A diplomate of the American Board of Clinical Chemistry and a fellow of the National Academy of Clinical Biochemistry, Dr. Demers holds a PhD in biochemistry from the State University of New York and an AB in biology from Merrimack College—where in 2011 he was awarded an honorary doctor of science. Dr. Demers is a distinguished professor emeritus of medicine and pathology at the Pennsylvania State University College of Medicine
Director of Operations: Engineering and Manufacturing
Shafie Kureshy joined AutoGenomics in 2001 and is an integral part of the Systems Development and Operations teams. Shafie played a key role leading a team of engineers to design and deploy the AutoGenomics instrument platforms and consumable lines. In an operational role, Shafie and his team oversee the production of instruments and performance of internal manufacturing operations. Prior to AutoGenomics, Shafie was part of the Engineering team at Behring Diagnostics developing immunoassay diagnostic instruments. Shafie has a Bachelors of Business Administration in IT from Baylor University.
Manager of Consumables
Ping Wang joined AutoGenomics in 2006 as part of the Systems Development team where he specialized in optical system development and production. In 2012, Ping Wang was promoted to Operations and led the team to manufacture AutoGenomics’ INFINITI instruments and consumables. Prior to AutoGenomics, Ping Wang was part of the R&D team at Motic developing digital microscopes for use in pathology. Ping Wang has a M. Sc. in Mechanical Engineering from Harbin Engineering University and B. Sc. in Mechanical Engineering from Harbin Institute of Technology in China.
Director of QC
Paige Onori joined AutoGenomics Quality Control Team in 2007 to manage testing of medical device instruments as well as assay consumables. Paige was appointed Director of Quality in 2016 and led her team to improve process controls for the instrument and consumable production lines. Prior to AutoGenomics, Paige worked in the genetics lab at Cal State San Marcos where she earned her BS in Biology Pre-Med while also working in the Veterinary Emergency/Specialty field for 10 years. Her experience includes being the Quality Assurance Manager for NuFACE where she succeeded in getting their MDSAP Certification in 2019.